4Bio Capital, of London, appointed Kenya Honda to its scientific advisory board.
Cerevel Therapeutics LLC, of Boston, appointed Kathleen W. Tregoning chief corporate affairs officer.
Cytovance Biologics LLC, of Oklahoma City, appointed John Mott vice president of development.
Eyepoint Pharmaceuticals Inc., of Watertown, Mass., appointed Jay S. Duker chief strategic scientific officer.
Kiadis Pharma NV, of Amsterdam, the Netherlands, appointed Ray Barlow chief business officer and Govert Schouten head of innovation.
Nurix Therapeutics Inc., of San Francisco, appointed Jason Kantor senior vice president, finance and investment strategy.
Phathom Pharmaceuticals Inc., of Florham Park, N.J., appointed Todd Branning chief financial officer.
Turning Point Therapeutics Inc., of San Diego, appointed Andrew Partridge executive vice president and chief commercial officer.
Vertex Pharmaceuticals Inc., of Boston, appointed E. Morrey Atkinson senior vice president and head of commercial manufacturing and supply chain.
Viacyte Inc., a San Diego, appointed Brittany Bradrick chief financial officer.
Vir Biotechnology Inc., of San Francisco, appointed Elliott Sigal to its board.